NCT07220408PHASE2Recruiting
Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis
Telios Pharma, Inc.
Start Date
10/23/2025
Completion Date
2/1/2026
Summary
In this prospective, Phase 2, randomized, double-masked, vehicle controlled study, approximately 60 eligible subjects will be randomized 1:1 to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally. The study comprises of a screening and treatment period using the conjunctival allergen challenge model to evaluate TL-925 for the treatment of allergic conjunctivitis.
Eligibility Criteria
Age Range: 18 years to No maximum
Inclusion Criteria:
* Individuals aged 18 years or older
* Female subjects of childbearing potential and their male partners must both use a highly effective contraception method during the study.
* Documented history of ocular allergies and a positive skin test reaction to a seasonal (grass, ragweed, tree pollen) or perennial (cat dander, dog dander, dust mites, cockroach) allergen as confirmed by an allergic skin test conducted at Visit 1 or within the past 60 months.
* Calculated best-corrected visual activity
* Positive bilateral CAC reaction
Exclusion Criteria:
* Any systemic or ocular disease currently producing ocular redness and/or ocular discomfort, or that may interfere with the conduct of the study.
* Any ocular surgical intervention within the last 3 months OR refractive surgery within the last 6 months
* Any ongoing ocular infection (bacterial, viral or fungal)
Interventions
DRUG
TL-925
DRUG
Placebo
Conditions
Allergic Conjunctivitis
Locations
Advancing Vision Research
Smyrna, Tennessee 37167
United States